SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-22-007327
Filing Date
2022-03-21
Accepted
2022-03-21 08:01:01
Documents
58
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 2894596
2 ex21-1.htm EX-21.1 4376
3 ex23-1.htm EX-23.1 3446
4 ex31-1.htm EX-31.1 11869
5 ex31-2.htm EX-31.2 11884
6 ex32-1.htm EX-32.1 6711
7 ex32-2.htm EX-32.2 6829
  Complete submission text file 0001493152-22-007327.txt   8139970

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE lixt-20211231.xsd EX-101.SCH 48044
9 XBRL CALCULATION FILE lixt-20211231_cal.xml EX-101.CAL 38262
10 XBRL DEFINITION FILE lixt-20211231_def.xml EX-101.DEF 240434
11 XBRL LABEL FILE lixt-20211231_lab.xml EX-101.LAB 402742
12 XBRL PRESENTATION FILE lixt-20211231_pre.xml EX-101.PRE 300749
52 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1093390
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39717 | Film No.: 22754246
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences